Literature DB >> 3140604

Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma.

M Gowen1, G E Nedwin, G R Mundy.   

Abstract

It is likely that immune cells in the bone marrow produce factors which are involved in the local control of bone remodeling. Immune cell products such as interleukin-1 and the tumor necrosis factors are potent stimulators of bone resorption in vitro. In this paper, we have studied the effects of recombinant murine interferon-gamma on bone resorption stimulated by these agents and the systemic calcium-regulating hormones 1,25(OH)2 vitamin D3 and parathyroid hormone. We found that interferon-gamma completely abolished bone resorption stimulated by the cytokines interleukin-1, tumor necrosis factor alpha and tumor necrosis factor beta. In contrast, parathyroid hormone- and 1,25(OH)2 vitamin D3-stimulated bone resorption were not significantly affected by the addition of interferon-gamma under the same conditions. Parathyroid hormone-stimulated bone resorption was inhibited slightly when larger concentrations of interferon-gamma were used for more prolonged periods. The inhibitory effects on cytokine-stimulated bone resorption occurred at interferon concentrations of 100 U/ml (half-maximal) to 300 U/ml (complete inhibition). This relatively selective inhibition of cytokine-stimulated bone resorption by an immune cell product may have physiological significance in the local control of trabecular bone volume and bone remodeling.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3140604     DOI: 10.1002/jbmr.5650010511

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  20 in total

1.  Is there a causal role for IL-1 in postmenopausal bone loss?

Authors:  R Pacifici
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

2.  Talc granulomatosis in the rat. Involvement of bone in the acute-phase response.

Authors:  A Marusić; K Kos; A Stavljenić; S Vukicević
Journal:  Inflammation       Date:  1990-04       Impact factor: 4.092

3.  Constitutive and inducible expression of HLA class II determinants by human osteoblast-like cells in vitro.

Authors:  H Skjødt; D E Hughes; P R Dobson; R G Russell
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

4.  Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice.

Authors:  M Sabatini; B Boyce; T Aufdemorte; L Bonewald; G R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Bone loss from high repetitive high force loading is prevented by ibuprofen treatment.

Authors:  N X Jain; A E Barr-Gillespie; B D Clark; D M Kietrys; C K Wade; J Litvin; S N Popoff; M F Barbe
Journal:  J Musculoskelet Neuronal Interact       Date:  2014-03       Impact factor: 2.041

Review 6.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

7.  Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption.

Authors:  C W Löwik; P H Nibbering; M van de Ruit; S E Papapoulos
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Evidence that interleukin-1 mediates its effects on bone resorption via the 80 kilodalton interleukin-1 receptor.

Authors:  I R Garrett; T A Guise; L F Bonewald; R Chizzonite; G R Mundy
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

9.  Comparison of osteogenic differentiation of embryonic stem cells and primary osteoblasts revealed by responses to IL-1β, TNF-α, and IFN-γ.

Authors:  Laura E Sidney; Glen R Kirkham; Lee D Buttery
Journal:  Stem Cells Dev       Date:  2014-01-23       Impact factor: 3.272

10.  Interactions of tumor necrosis factor with local and systemic factors in fetal rat limb bones.

Authors:  G Shankar; P H Stern
Journal:  Calcif Tissue Int       Date:  1992-11       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.